Can an immune booster help chemotherapy fight metastatic breast cancer?
Disease control
Terminated
This trial tests whether adding an experimental immunotherapy called eftilagimod alpha to standard chemotherapy (paclitaxel) can help people with HER2-negative metastatic breast cancer live longer. The study first finds the best dose of eftilagimod alpha, then compares the combin…
Phase: PHASE2, PHASE3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC